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Manipulation of the ubiquitin proteasome system (UPS) is emerging as a common theme in viral patho-
genesis. Some viruses have been shown to encode functional homologs of UPS enzymes, suggesting that a
systematic identification of these products may provide new insights into virus-host cell interactions. Ubiq-
uitin-specific proteases, collectively known as deubiquitinating enzymes (DUBs), regulate the activity of the
UPS by hydrolyzing ubiquitin peptide or isopeptide bonds. The prediction of viral DUBs based on sequence
similarity with known enzymes is hampered by the diversity of viral genomes. In this study sequence align-
ments, pattern searches, and hidden Markov models were developed for the conserved C- and H-boxes of the
known DUB families and used to search the open reading frames (ORFs) of Epstein-Barr virus (EBV), a large
gammaherpesvirus that has been implicated in the pathogenesis of a broad spectrum of human malignancies
of lymphoid and epithelial cell origin. The searches identified a limited number of EBV ORFs that contain
putative DUB catalytic domains. DUB activity was confirmed by functional assays and mutation analysis for
three high scoring candidates, supporting the usefulness of this bioinformatics approach in predicting distant
homologues of cellular enzymes.
The posttranslational modification of proteins by ubiquitin
(Ub) and Ub-like molecules (UbLs) and the degradation of
polyubiquitinated substrates by the proteasome regulate fun-
damental cellular processes, including cell growth and differ-
entiation, intracellular signaling, protein trafficking, apoptosis,
and the recognition of virus-infected or malignant cells by the
host immune response (21, 27, 33, 44, 46). Modulation of the
ubiquitin-proteasome system (UPS) is emerging as a central
theme in viral pathogenesis, and several examples have been
reported of viral proteins that mimic or redirect the activity of
the system in order to modify the cellular environment in favor
of virus persistence or replication (22, 28, 31, 34, 41, 45). Thus,
the identification of viral products that interfere with the UPS
may yield new insights on important features of viral patho-
genesis and could lead to the development of new means of
therapeutic intervention.
Conjugation of Ub or UbLs is achieved through the activity
of a cascade of enzymes, including activating enzymes (E1s),
conjugating enzymes (E2s), and specific ligases (E3s) that cat-
alyze the covalent linkage of the modifier to Lys residues in the
substrate (11). In addition, deconjugating enzymes act as reg-
ulators of the system by maintaining the pool of free Ub and
UbLs and by determining the rate of turnover of the conju-
gates (14, 50). In line with this proposed regulatory function,
recent evidence points to a critical role of Ub deconjugases
(deubiquitinating enzymes [DUBs]) in intracellular signaling,
as exemplified by the activation of the transcription factor
nuclear factor-B (NF-B) by cylindomatosis tumor suppres-
sor, A20, Cezanne, and ubiquitin-specific protease 31 (25, 33)
and by the initiation of DNA repair by USP1 (37).
Based on similarity with known family members, the human
DUBs have been classified in five subfamilies including: ubiq-
uitin C-terminal hydrolases (UCHs), ubiquitin-specific pro-
teases (USPs), Machado-Joseph disease proteases (MJDs or
Josephins), ovarian tumor proteases (otubains, OTUs), and
the JAMM (Jab1/MPN/Mov34 metalloenzyme) motif pro-
teases (2, 38). With the exception of JAMMs, the DUBs are
cysteine proteases identified by a catalytic triad of Cys, His,
and Asp/Asn residues and by the presence of conserved amino
acid domains known as Cys- and His-boxes (C- and H-boxes,
respectively) that are unique for each family (38). Mutational
studies have shown that the Asp/Asn residue is not essential
for catalytic activity, although it may contribute to the enzy-
matic activity by stabilizing the active-site thiolate and imid-
azolium ion pair (26, 35). The JAMM metalloproteases lack a
C-box, while two conserved His residues in the JAMM motif
were shown to be essential for activity (49).
Proteins with DUB activity are encoded in the genome of
human adenovirus, herpesvirus, coronavirus, and bunyavirus
(5, 6, 18, 29, 42). Furthermore, DUB activity was recently
demonstrated in proteins encoded by some pathogenic bacte-
ria that lack an intrinsic UPS (40, 52), suggesting that these
enzymes play specific roles in the regulation of both viral and
bacterial infection. Although these findings make the system-
atic identification of microbial DUBs a worthy endeavor, the
task is complicated by the wide sequence variation of the
known enzymes. Moreover, viral and bacterial proteins are
often considerably different in sequence and domain organi-
zation compared to their mammalian counterparts, which fur-
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ther hampers the identification of distant functional homo-
logues.
We have used a bioinformatics strategy here to identify
putative virus-encoded DUBs. To overcome the difficulty
posed by sequence variation, we focused on the conserved C-
and H-boxes. Family-specific sequence alignments, pattern
searches, and hidden Markov models (HMMs) were generated
based on the amino acid sequences of known members of the
five DUB subfamilies and then used to search a custom-made
database of open reading frames (ORFs) from Epstein-Barr
virus (EBV), a human gamma herpesvirus that establishes la-
tent infections and is associated with a broad spectrum of
malignancies of lymphoid and epithelial cell origin.
MATERIALS AND METHODS
Data sets. The sequences of DUBs were extracted from the UniProt database
version 51.2 (4). The DUB data set consisted of both experimentally verified
human enzymes and highly conserved sequence homologs (Table 1). For families
with fewer than 10 human sequences, homologues from other species were
included. The sequence of the B95.8 EBV genome (3) was obtained from NCBI
GenBank (Refseq NC_007605). The sequences of 75 annotated EBV ORFs were
retrieved from the Swiss-Prot database. In addition, ORF prediction was carried
out with the getORF program available in the EMBOSS package (39), with a
length cutoff setting between 150 and 5,000 amino acids (aa), which resulted in
106 predicted ORFs. For ORFs annotated in Swiss-Prot, the progressive number
assigned to the predicted ORFs was substituted with the corresponding gene
symbol.
DUB searches. (i) Sequence alignment. Sequence comparisons between the
human DUBs and the EBV ORFs were carried out by using CLUSTAL W (47)
and BLAST (1). CLUSTAL W calculates multiple sequence alignments and was
therefore used to investigate whether any of the EBV ORFs clusters with the
specific DUB subfamilies. BLAST searches were used to identify putative C- and
H-boxes. To this end, members of each DUB family were aligned by using
CLUSTAL W, and conserved catalytic domains were extracted with the GoCore
program (http://www.helsinki.fi/project/ritvos/GoCore/). The C- and H-box do-
mains of each family were defined on the basis of the conserved regions (UCH,
C-box 23aa and H-box 24aa; USP, C-box 16aa and H-Box 21aa; OTU, C-box
19aa and H-box 14aa; MJD, C-box 21aa and H-box 14aa; JAMM domain 25aa),
and the sequences were then searched against the EBV ORF database. Hits with
arbitrarily chosen E-values of 10 and containing Cys or His residues were
selected for further analysis.
(ii) Pattern search. C- and H-box specific patterns were constructed to search
for putative catalytic domains. The C- and H-boxes of each DUB family were
aligned with respect to the conserved Cys and His residues, and search patterns
were manually derived from the sequence alignments based on the physicochem-
ical properties.
(iii) HMM search. HMMs were constructed by using the HMMER (17) suite
of programs. For each DUB subfamily the HMMs were trained with multiple
sequence alignments of C- and H-boxes from a nonredundant set of sequences
(Table 1, HMM training set). The HMM results were further categorized
based on E-values and raw scores. In every search with subfamily-specific
HMMs, matches with E-values of 25 were selected and manually screened
for the presence of Cys or His residues in the alignment. Candidates con-
taining putative C- or H-boxes were further categorized based on the HMM
scores of the domains. The HMM score is a base 2 log of the probability of
alignment to the HMM divided by the probability of random alignment. A
score of zero represents 50% likelihood that the sequence is a true match to
the model. Since the EBV ORF database contains 106 entries, scores greater
than 6.7 correspond to a 99% probability to detect true homologs while a
score of 6.6 corresponds to 1% probability. Due to the fact that the ge-
nomes of viral and other pathogenic organisms undergo higher mutation rates
(16), low thresholds of statistical parameters were used to detect catalytic
domains of DUBs.
(iv) Conserved Cys and His residue search. Homologous proteins that are
conserved between members of at least one subfamily of human herpesviruses
(-HHVs: herpes simplex virus type 1 [HSV-1], HHV1, HSV-2, HHV2, varicel-
la-zoster virus, and HHV3; -HHVs: human cytomegalovirus, HHV5, HHV6,
HHV7; and -HHVs: EBV, HHV4, Kaposi sarcoma herpesvirus, and HHV8)
were identified by using BLAST with a cutoff E-value of 0.01, corresponding 99%
probability to be a true homolog. Homologous proteins were then aligned by
using Vector NTI (32), and the multiple alignments of each cluster were scanned
for the presence of conserved Cys and His residues. Sequences flanking the
conserved residues were searched for putative C- and H-boxes using the
HMMs.
Functional validation of candidate DUBs: cloning of EBV ORFs into prokary-
otic expression vector. ORFs derived from the B95-8 virus were transferred from
the GATEWAY expression vector pDONR207 (48) to the prokaryotic expres-
sion vector pDEST-GST (ampicillin resistance), and E. coli DH5 was used for
transformation.
Ub-GFP construct. Green fluorescent protein (GFP) was amplified by PCR
from pEGFP-N1 vector (Clontech, Palo Alto, CA) with the sense primer
5-GTTTTCAGATCTAAAGGAGAAGAGCTGTTCACCGGCGTGAGCA
AGGGCGAGGAGCTGTTCACC-3 and the antisense primer 5-GTTCTC
GAGCTTGTACAGCTCGTCCATGCCGAGAGTGAT-3 and cloned in the
BglII and XhoI sites of the pACYCDuet-1 vector (Novagen, Darmstadt,
Germany). Ubiquitin was amplified by PCR from an Ub-Gal plasmid with
the primer 5-GTTGAATTCAATGCAAATCTTCGTGAAGACTCTGACT
GGTA-3 and the antisense primer 5-GTTAGATCTGAACCCACCTCTG
AGACGGAGTACCA-3 and inserted in frame in the EcoRI and BglII sites
of the pACYCDuet-1 vector containing GFP. The underlined sequences
represent restriction sites.
DUB assays. The GST-ORFs and Ub-GFP reporter plasmids were cotrans-
fected by electroporation in competent BL21(DE3) bacteria that lack endoge-
nous DUBs (9). Antibiotic-resistant colonies were selected in LB agar supplied
with 100 	g of ampicillin/ml and 30 mg of chloramphenicol/ml. Exponentially
growing bacteria (OD at 600 nm of 0.5) were induced for 5 h at 30°C with 0.5 mM
IPTG (isopropyl--D-thiogalactopyranoside) and then lysed by sonication in
phosphate-buffered saline supplemented with protease inhibitors (Complete
Mini protease inhibitor cocktail tablets; Roche, Germany). The lysates were
clarified by centrifugation for 10 min at 13,000 rpm, and cleavage of the reporter
was analyzed by fractionation in acrylamide bis-Tris 4 to 12% precasted gradient
gel (Invitrogen), followed by Western blotting. After transfer to polyvinylidene
difluoride membrane (Millipore), the filter was blocked in phosphate-buffered
saline supplemented with 5% nonfat milk and 0.1% Tween 20 and incubated for
1 h with anti-rabbit-GFP serum (Abcam, Cambridge, United Kingdom) diluted
TABLE 1. Data sets of DUBs used in this study
Protein family Characteristic domain No. of humanDUBs
No. of verified
DUBsa
No. of
orthologs
No. of DUBs
in pattern
search setb
No. of DUBs in
HMM training setd
C-box H-box
USP Peptidase 19 45 37 45 36 42
UCHL Peptidase 12 4 4 15 19 10 8
OTU OTU 8 5 9 17 10 11
MJD Josephin 3 1 9 12 7 7
JAMMc MPN 8 2 29 34 21
a That is, the number of DUBs with experimentally verified enzymatic activity.
b Due to the small number of identified sequences in the human UCH, OTU, JAMM, and MJD subfamilies, orthologs from other species were included in the
data set.
c The JAMM metalloproteases contain only H-box domains, and sequence homologs with catalytic. His residues were considered for deriving the patterns.
d Only C- and H-boxes with 90% sequence identity were used for training the HMMs.
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1:10,000. After incubation for 1 h with peroxidase-conjugated goat anti-rabbit
serum, the complexes were visualized by enhanced chemiluminescence (GE
Healthcare, United Kingdom). For the enzyme kinetic assays, GST-USP19,
GST-USP19mut, GST-BPLF1-N, GST-BSLF1, and GST-BXLF1 were purified
from bacteria lysates (50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 5 mM MgCl2, 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol) by
incubation for 90 min at 4°C with a solution of 10 mM glutathione in 50 mM
Tris-Cl (pH 8.0), and the protein concentrations were determined with a Bio-
Rad protein assay. Hydrolysis of the fluorogenic substrate ubiquitin-AMC (Ub-
AMC, SE211; Biomol) was assayed at 30°C in 100 	l of assay buffer (50 mM
Tris-Cl [pH 7.5], 150 mM NaCl, 2 mM EDTA, 2 mM dithiothreitol) containing
200 nM concentrations of the enzyme, and the Vmax and Km of the reactions were
calculated by titrating the substrate at concentrations ranging between 0 and 20
mM. The fluorescent product was measured by using a spectrofluorimetry plate
reader at 380-nm excitation and 460-nm emission wavelengths. To block the
DUB activity, 10 mM N-ethylmaleimide (NEM; Sigma) was added to the assay
buffer.
Site-directed mutagenesis. Point mutations of the predicted catalytic Cys res-
idues of BPLF1, BSLF1, and BXLF1 genes were engineered by using a
QuikChange site-directed mutagenesis kit according to the manufacturer’s pro-
tocol (Stratagene). Two BPLF1 mutants (C61A and C65A), three single mutants
(C462A, C824A, and C819A), and one double mutant (C824/819A) of BSLF1
and two mutants of BXLF1 (C84A and C491A) were constructed. All constructs
were then sequenced to verify that only the desired mutations had been intro-
duced.
RESULTS
Four search strategies were used to identify putative DUBs
encoded in the EBV genome: (i) sequence alignment with the
conserved C- and H-boxes of known DUB families, (ii) pattern
search of conserved catalytic domains, (iii) HMM-based
searches, and (iv) identification of Cys and His residues that
are conserved in homologues encoded by other members of
the HHV family, followed by an HMM search.
Sequence alignment searches. A first attempt to identify
putative DUBs was performed using CLUSTAL W to align the
EBV ORFs with the human DUB data set. Three ORFs clus-
tered with specific DUB subfamilies, BGLF4 and BBLF4 clus-
tered with the OTU subfamily and BcLF1 ORF aligned with
JAMMs (not shown), but the homologous regions did not
contain Cys or His residues, and these viral ORFs are there-
fore unlikely to possess enzymatic activity. Since alignment of
the entire amino acid sequence may not detect homology re-
stricted to short domains that are critical for enzymatic activity,
BLAST was used to identify EBV ORFs containing sequences
of homology with the conserved C- and H-boxes of each DUB
family using an arbitrary cutoff E-value of 10. Twenty-five
candidates containing Cys or His residues in homologous re-
gions were found in this search (see Table S1 in the supple-
mental material), including for example, the BBRF3 ORF that
contains a region of strict homology with the USP C-box (E-
value 
 0.018).
Pattern search. Additional search strategies were conducted
to achieve a more stringent assessment of the likelihood that
the identified domains might be true C- or H-boxes homo-
logues. Family-specific search patterns were derived from the
aligned C- and H-box sequences of the known DUBs. To
increase the stringency of the search, when fewer than 10
family members were found in the human data set, homo-
logues from other species were also included in the alignment.
The derivation of search patterns for the C- and H-boxes of the
UCH family is illustrated in Fig. 1, and the search patterns for
USP, OTU, MJD and JAMM families are given in Fig. S1A to
D in the supplemental material. In a first attempt, stringent
search patterns were derived for each DUB family (UCH,
C-box 11/11 and H-box 7/16; USP, C-box 8/7 and
H-box17/3; OTU, C-box8/10 and H-box8/5; MJD,
C-box 10/10 and H-box 6/7; and JAMM motif 7/17)
by including at each position all residues observed in the data
set (Fig. 1B, boldface residues) and then used to search the
EBV ORF data set, allowing for only a single mismatch. The
derived patterns were in all cases able to identify the DUBs
belonging to the family but failed to identify any candidate in
the EBV ORFs (results not shown), suggesting that they may
be too stringent to recognize distant homologues. Less-strin-
gent search patterns were then derived by allowing at each
position additional amino acids with similar physicochemical
characteristics or, when residues with different physicochemi-
cal characteristics were observed, all amino acids (indicated by
an “X” in Fig. 1B and in Fig. S1A to D in the supplemental
material). Regions of similarity with the C- and/or H-boxes of
different DUB families were identified in 30 EBV ORFs (see
Table S2 in the supplemental material). Four ORFs contained
at least one putative C-box and one H-box, while three ORFs
contained only one putative C-box and twenty-three ORFs
contained one or more H-box-like domain.
HMM search. Family-specific HMMs were derived for the
aligned C- and H-boxes of the different DUB families. In order
to increase the probability of identifying distant homologs, only
sequences with90% identity were included in the training set
(Table 1). Since the EBV ORF database contains only 106
sequences and the HMMs are based on short C- and H-box
domains of 13 to 24 aa, high E-values and low scores were
expected. HMM alignments with E-values of 25 were there-
fore considered for further analysis. All hits containing Cys or
His residues were further categorized based on the HMM
scores (Table 2). Scores of 0, corresponding to more than
50% likelihood to be a true match, were considered high.
Intermediate scores were between 0 and 6.6 (down to 1%
probability to be a true match), while scores less than 6.6
were considered low. Seven EBV ORFs—BALF2, BALF5,
BBRF3, BcLF1, BERF3-BERF4, BRLF1, and the predicted
ORF88—contained at least one C- or H-box domain with
score above 0, suggesting a potential homology with the
corresponding DUB domains. Two ORFs—BNRF1 and
BPLF1—contained both C- and H-box-like domains with
scores 6.6, and eighteen additional ORFs contained either
a C- or an H-box-like domain with scores of less than 6.6.
Search for conserved Cys and His residues. A further at-
tempt to identify candidate DUBs was undertaken based on
the assumption that amino acid residues that are critical for
protein function may be conserved in homologues encoded by
different members of the HHV family. Homologous ORFs
encoded by the known HHVs were identified by sequence
comparison, and the conserved Cys and His residues were
located. Twenty-one EBV ORFs contain at least one Cys or
His residue that is conserved in homologues encoded by all
HHV members, while Cys or His residues conserved only in -
or -HHVs were detected in two and seven ORFs, respec-
tively; thirteen EBV ORFs shared conserved Cys or His resi-
dues only with homologues encoded by the other member of
the -HHV subfamily, KSHV, that resembles EBV in cell
tropism and oncogenic capacity (see Table S3 in the supple-
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mental material). The sequences adjacent to the conserved
residue were searched for putative C- and H-boxes using the
DUB family specific HMMs. Nine EBV ORFs were found to
contain conserved Cys or His residues located in regions ho-
mologous to the DUB C- or H-boxes, and one ORF, BGRF1/
BDRF1, contained both C- and H-box homologous domains
(see Table S3 in the supplemental material).
DUB score and exclusion criteria. A relatively large number
of candidate DUBs were identified by at least one search, and
several were identified by more than one. To select the most
likely candidates for functional studies, scoring criteria were
devised for each search, and these were then compiled in a
global DUB score. The scores assigned to each search reflected
the likelihood of identifying candidates that possess critical
features associated with DUB activity (see Table S4 in the
supplemental material). Candidates identified by the BLAST
search were given a score of 1, 2, or 3 depending on the degree
of similarity with DUB sequences. Candidates identified by the
pattern search were scored 1 or 2 based on the presence of C-
or H-box-like domains or both, while the score of candidates
identified by the HMM considered both the presence of C- and
H-box-like domain and their HMM scores (high 
 0, inter-
mediate 
 between 0 and 6.6, or low 
 6.6). The same
scoring system was used for candidates identified by the pres-
ence of conserved Cys and His residues. The scores of 58
candidates identified by at least one search are shown in Table
S4 in the supplemental material. Two ORFs—BGRF1/BDRF1
and BPLF1—were identified by the four searches, nine ORFs
were identified by three searches, twenty-two ORFs were iden-
tified by two searches, and twenty-five ORFs were found by
only one search. All candidates identified in at least three
searches and five candidates identified by two searches re-
ceived scores of4. This group included 16 ORFs, all of which
were identified by HMM, and 7 were shown to contain con-
served Cys or His residues.
In order to further restrict the number of candidates to be
validated by functional studies, ORFs with scores of 4 were
scrutinized for the presence of structural constraints that could
prevent DUB activity. The locations of the putative C- and
H-boxes were mapped relative to each other and to other
protein domains of known function (Fig. 2). Based on this
domain analysis, the BBRF3 and BILF1 ORFs could be ex-
cluded since their putative C- and H-boxes are located in
transmembrane regions, which would preclude DUB activity.
Analysis of the site of expression in EBV-infected cells, ex-
pression during different phases of the virus cycle, and func-
tional annotation (Table 3) revealed that some of the high-
scoring candidates are structural proteins or glycoproteins
associated with the virus capsid and envelope. These proteins
are unlikely to possess enzymatic activity, although this cannot
be excluded a priori. The remaining candidates include imme-
diate-early, early, late, or latent proteins that are expressed in
FIG. 1. Derivation of search patterns for the UCH subfamily catalytic domains. (A) The aligned amino acid sequences of the catalytic Cys and
His-box regions of UCH (peptidase C12) family members are shown. The numbers above the alignment correspond to the amino acid position
relative to the catalytic Cys and His residues. Polar residues are colored blue, hydrophobic residues are gray, and small residues (Gly and Ala) are
white. (B) Stringent search patterns were derived by including at each position all amino acids observed in the aligned DUB sequences (indicated
in bold). Less-stringent patterns were then obtained by allowing amino acids with similar physicochemical properties (indicated in italics). When
different types of amino acids were observed at a given position, all amino acids were allowed in the pattern (indicated by X).
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the nucleus or, in one case, in the cytoplasm of the infected
cells or are components of the viral tegument. It is noteworthy
that two tegument proteins were found in the group with the
highest DUB score and one of them, the protein encoded by
the BPLF1 ORF, was previously shown to possess DUB activ-
ity (23, 42).
Functional validation of the candidates. In order to validate
the DUB score, GST fusions of 11 EBV ORFs with scores of
4 and an approximately equal number of ORFs with scores
of 3 were tested for their capacity to hydrolyze a Ub-GFP
reporter plasmid coexpressed in bacteria. The results of a rep-
resentative assay wherein the ORFs were tested alongside the
human USP19 and a catalytic mutant that lacks enzymatic
activity are shown in Fig. 3.
The reporter was efficiently cleaved by USP19, as confirmed
by the detection of both free GFP (Fig. 3A) and free ubiquitin
(data not shown), while cleavage was abolished by mutation of
the catalytic Cys residue in the USP19Mut. In line with the
reported DUB activity of this ORF, Ub-GFP was cleaved al-
most completely in bacteria expressing the N terminus of
BPLF1 (Fig. 3A and B). The levels of cleavage significantly
above background were also detected with BSLF1 and BXLF1,
while the activity of BGRF1 and BALF5 was just below the
cutoff (3 the mean percent cleavage in the presence of ORFs
with scores3 [Fig. 3B]). The expression of the fusion proteins
was in all cases confirmed in Western blots probed with anti-
GST antibodies (data not shown). In order to further charac-
terize their DUB activity, bacterially expressed GST-BPLF1-N,
GST-BSLF1, and GST-BXLF1 were purified, and their en-
zyme activity was assayed by cleavage of the fluorogenic sub-
strate Ub-AMC (Fig. 3C). The three EBV ORFs hydrolyzed
Ub-AMC with different kinetics and Km values, suggesting very
different affinities for the substrate, but the specificity of the
reaction was in all cases confirmed by blocking with the cys-
teine protease inhibitor NEM. Interestingly, the enzymatic ac-
tivity of BSLF1 and BXLF1 relative to BPLF1 was significantly
improved when equal amounts of immunoprecipitated pro-
teins expressed in mammalian cells were compared for the
cleavage of Ub-AMC (compare Fig. 3C and D), suggesting that
posttranslational modifications that are not achieved in bacte-
ria cells may be required for optimal activity.
In order to further validate the DUB activity of the candi-
dates, the predicted catalytic Cys residues in BPLF1, BSLF1,
and BXLF1 were mutated to Ala by using PCR-mediated
site-directed mutagenesis, and the enzymatic activity of recom-
binant GST tagged proteins was tested against the Ub-AMC
substrate (Fig. 4). Two putative C-boxes were predicted in the
BSLF1 and BXLF1 ORFs, while a single domain containing
two Cys residues was predicted in BPLF1. Alignment of the
corresponding sequences in other members of the HHV family
revealed that, while BPLF1 Cys61 and BSLF1 Cys819 and
Cys824 are conserved in all HHVs, other potentially catalytic
Cys residues identified by the bioinformatics search are unique
for EBV or shared only by some of the family members. Mu-
tation of the conserved C61 of BPLF1 to Ala abolished the
enzymatic activity, while the C65A mutation had no effect,
confirming that C61 is the catalytic residue in the C-box (Fig.
4). Single mutation of the nonconserved C462 and conserved
C824 of BSLF1 did not affect the enzymatic activity, while the
activity of the C819A mutant was significantly reduced. Inter-
estingly, the hydrolysis of Ub-AMC was further decreased in
the double mutant C819/824A, suggesting that C824 may partly
substitute for the catalytic C819 residue. Homologs of BXLF1
were present only in alpha- and gammaherpesviruses, and the
putative catalytic cysteine C491 is conserved only in gamma-
herpesvirus. Mutation of this residue abolished the enzymatic
activity of BXLF1, while mutation of the nonconserved C84
had no effect (Fig. 4). Thus, catalytic Cys residues were iden-
TABLE 2. Putative DUB catalytic boxes identified by the
HMM searcha
EBV ORF
C-box H-box
Type Score Type Score
BALF1 OTU -0.4
BALF2 OTU 1.9
UCH –6.4
BALF4 OTU –10.2 UCH –9.3
BALF5 USP 0.3
BaRF1 UCH –1.9
BBLF2 USP –2.9
BBLF4 MJD –15 OTU –4.3
BBRF2 USP –3.7
BBRF3 USP 7.8 OTU –6.7
UCH –9.8
BcLF1 OTU 1.3 OTU –4.2
USP –8.4
BcRF1 MJD –9.5
BDLF2 OTU –7.6
BERF3-BERF4 USP 0.69
OTU –7.9
MJD –8.3
BFRF2 OTU –6.8
BGLF1 OTU –1.6 OTU –7.7
BGLF2 OTU –4.6
BGLF3 OTU –5.3
BGRF1/BDRF1 MJD –10.9 MJD –8.1
BILF1 USP –0.6
BKRF1 USP –3
BLLF3 OTU –7.9
BMLF1 OTU –6.7
BMRF2 MJD –9.2
BNRF1 USP –3.9 OTU –2
UCH –9.1
BORF1 USP –4.2
BPLF1 USP –4.5 OTU –4.3
BRLF1 USP 0.9 OTU –6.3
OTU –4.4
BSLF1 OTU –7.8 OTU –6.8
BVRF2 USP –3.5 JAMM –16.2
BXLF1 USP –3.4 USP –13.2
BXLF2 USP –5.2
UCH –5.5
MJD –7.4
BXRF1 MJD –8.9
LMP1 MJD –8.4
LMP2 USP –1
ORF101 USP –2.5
ORF35 OTU –5.3
MJD –7.6
ORF42 OTU –9.6
ORF86 OTU –2.3
USP –4.5
ORF88 OTU –11.1 OTU 2.9
a The type of DUB domain found in each candidate is indicated as follows:
USP, ubiquitin-specific protease; OTU, ovarian tumor domain protease; UCH,
ubiquitin C-terminal hydrolase; MJD, Josephin domain protease. Boldfacing
indicates high scores (0); italics indicates intermediate scores (between 0 and
6.6); regular typeface indicates low scores (–6.6)
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tified by mutation analysis in BPLF1, BSLF1, and BXLF1,
confirming that the three EBV ORFs are bona fide viral
DUBs.
To finally validate our bioinformatics approach, the scoring
strategy used to identify BPLF1, BSLF1, and BXLF1 was ap-
plied to their homologues encoded by other human herpesvi-
ruses. All homologs of BPLF1 and BSLF1 received scores of
4, and several scored even higher than the EBV-encoded
protein (Table 4). This is in line with the reported DUB activity
of several BPLF1 homologues. In agreement with the very low
sequence similarity of the BXLF1 homologues expressed in
alpha- and gammaherpesvirus these ORFs received very low
DUB scores, suggesting that this protein may have different
functions in different viruses.
DISCUSSION
In this study we used a bioinformatics approach to identify
distant functional homologues of human ubiquitin deconju-
gases encoded in the EBV genome. This task is complicated by
the great genetic variability of viruses, which results in poor
sequence conservation even between homologous proteins ex-
pressed by different members of the same virus family. Indeed,
currently used bioinformatics tools, such as BLAST searches
FIG. 2. Mapping of the putative C- and H-box domains in ORFs with high DUB scores. The positions of the putative C- and H boxes identified
by the different searches and the Cys and His residues that are conserved in homologues encoded by other HHV family members are indicated.
Putative transmembrane domains were identified by a TMHMM search in the candidate ORFs and are indicated as yellow hexagonal regions. In
BBFR3, BILF1, and ORF88 the C- and/or B-boxes overlap with or flank transmembrane domains.
TABLE 3. ORF annotation and filtering criteria
EBV ORF DUBscorea EBV protein
Homologue Expression in
virus cycle Location Function
b Filter
HSV CMV KSHV
BBRF3 9 Glycoprotein M gM gM gM Late Envelope M (–)
BcLF1 7 Major capsid protein UL19 UL86 ORF25 Late Capsid C –
BALF5 7 DNA pol catalytic subunit UL30 UL54 ORF9 Early Nucleus R
BGRF1/BDRF1 7 DNA packaging, Terminase UL15 UL89 ORF29 Late Nucleus P
BNRF1 6 Major tegument protein ORF75 Late Tegument T
BPLF1 6 Large tegument protein UL36 UL48 ORF64 Late Tegument T
BXLF2 5 gp85, gH homologue UL22 UL75 ORF22 Late Envelope M (–)
ORF35 5 Hypothetical
ORF88 5 Hypothetical –
BALF2 5 ssDNA binding protein UL29 UL57 ORF6 Early Nucleus R
BSLF1 5 Helicase/primase complex UL52 UL70 ORF56 Early Nucleus R
BILF1 4 gp64, constitutive GPCR Early Membrane M (–)
BERF3-BERF4 4 EBNA3C Latent Nucleus L
BaRF1 4 RNase reductase UL40 ORF60 Early Nucleus N
BRLF1 4 Rta, transactivator ORF50 I-Early Nucleus S
BXLF1 4 Thymidine kinase UL23 ORF21 Early Nucleus N
a For the details on the scoring, see Table S4 in the supplemental material.
b Classification of protein based on function: C, capsid; M, membrane protein; N, nucleotide metabolism; L, latency; P, packaging; R, replication; S, signaling,
transactivator, transcription factor; T, tegument.
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or more sophisticated threading programs that use sequence
alignment and protein fold recognition algorithms, fail to de-
tect homologies between known viral and cellular DUBs, sug-
gesting that the structural properties of the viral proteases are
clearly distinct. This was recently confirmed by the crystal
structure of a DUB encoded by the murine gammaherpesvirus
M48 that, based on the arrangement of the active-site residues
and the architecture of the ubiquitin interacting interface, was
classified as the first member of a new class of DUBs (43).
We reasoned that, in spite of strongly divergent sequences, a
higher degree of conservation might be expected in regions
that are important for enzymatic activity. Thus, although the
homology between the catalytically relevant regions of viral
and cellular enzymes falls below the statistically significant
cutoffs used in conventional searches, distant homologues may
be identified using less-stringent search criteria. The human
genome encodes for approximately 95 DUBs subdivided in five
families (38). Although the sequences of individual DUBs vary
widely, the members of each family share a high degree of
homology in regions surrounding conserved Cys and His resi-
dues that form the catalytic core of the enzymes. We therefore
focused on the identification of EBV ORFs containing a re-
gion of homology with the C- and H-boxes of each DUB family
and scored the candidates based on the degree of homology
with the consensus sequences and on the presence of only one
or both types of consensus domains. Four different strategies
based on sequence alignment, pattern search, HMM motifs,
and detection of conserved Cys and His residues in the context
of HMM motifs were used to search for putative C- and H-
boxes. The use of multiple searches provides a distinct advan-
FIG. 3. Functional validation of the candidate DUBs. (A) Representative Western blot illustrating cleavage of the Ub-GFP reporter by a
restricted panel of EBV ORFs. BL21 cells were cotransfected with Ub-GFP, and the indicated ORF and protein expression was induced by
treatment with IPTG. Cell lysates were fractionated on 4 to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gradient gels, and GFP
was detected by Western blotting. Cleavage of the reporter in lysates expressing active DUBs is visualized by appearance of a free GFP band.
(B) Enzymatic activity of candidate EBV DUBs (score  4) and controls (score  3). The intensity of the bands corresponding to the uncleaved
reporter and free GFP was determined by densitometry, and the percent specific cleavage was calculated as follows: intensity of the free GFP band –
background/total GFP (uncleaved  cleaved) – background  100. A cutoff activity value was calculated as 3  the mean percent specific cleavage
in cells expressing ORFs with a score of 3. The mean of three experiments in which all of the ORFs were tested in parallel is shown in the figure.
(C) Time course of Ub-AMC hydrolysis. Ub-AMC (1.2 	M) was mixed with 200 nM concentrations of purified GST-USP19wt, GST-USP19mut,
GST-BPLF1-N, GST-BSLF1, and GST-BXLF1 in the absence (empty symbols) or presence (filled symbols) of NEM, and the reactions were
monitored for 180 min. The release of fluorescent AMC, expressed in arbitrary units (AU), shows the activity of these enzymes to cleave Ub-AMC.
The Km of the reactions was calculated in separate experiments and is indicated in the Figure. (D) Time course of Ub-AMC hydrolysis of BPLF1,
BSLF1, and BXLF1 expressed in mammalian cells. The ORFs were cloned in frame in the 3XFlag tag vector and expressed in HEK293 cells. The
proteins were immunoprecipitated from the transfected cells using antibodies to the Flag tag, and the cleavage of Ub-AMC was assayed as
described for panel C. Equal amounts of proteins were used in all enzymatic assays. The faster kinetics of Ub-AMC cleavage (compare panels C
and D) indicates that the enzymatic activity of mammalian expressed BSLF1 and BXLF1 is significantly improved compared to the proteins
expressed in bacteria.
VOL. 82, 2008 EBV ENCODES ACTIVE DEUBIQUITINATING ENZYMES 10483
tage since each search is biased by different criteria. Thus,
while sequence alignment scores for the presence of a contin-
uous sequence of homologous residues, the pattern search
restricts the hits to sequences that share similar residues at
critical positions in the motif and HMM gives a global score
based on the likelihood that a given residue will be found in
each position of the motif. A further refinement of the HMM
search was based on the assumption that functionally relevant
proteins will be conserved among members of a virus family,
and therefore conserved Cys and His residues will be found in
the putative catalytic domains. By assigning individual scores
to each of these searches and then combining the scores into a
global DUB score, we have identified 16 candidates with DUB
scores of 4 out of 106 annotated or predicted ORF in the
EBV genome. Five of the candidates were excluded from fur-
ther analysis because the putative catalytic domains are located
within or at the opposite sides for transmembrane domains or
because they are either known structural components of the
virus capsid or envelope glycoproteins and are therefore un-
likely to possess DUB activity.
A previously identified viral DUB encoded by the BPLF1
ORF was found among the high score candidates. BPLF1 is
the EBV homologue of UL36, a presumably multifunctional
protein of the alphaherpesvirus HSV-1. DUB activity was pre-
viously mapped to the N-terminal portion of UL36 by using a
functional proteomic approach based on labeling of total cell
extracts with and epitope-tagged, Ub-based suicide substrates
followed by immunoprecipitation, and identification of the la-
beled enzyme by mass spectrometry (23). Using a reporter
substrate that carries ubiquitin fused to GFP in a conformation
that mimics the ubiquitin precursors and, to some extent, a
true ubiquitinated substrate, we have now confirmed that the N
terminus of BPLF1 is a very potent ubiquitin deconjugase.
Interestingly, two additional ORFs in the high-score group,
BSLF1 and BXLF1, were also capable of cleaving Ub-GFP at
levels significantly above background. The enzymatic activity of
FIG. 4. Identification of the catalytic Cys residues by site-directed mutagenesis. Sequence alignments of the putative catalytic C-boxes in
BPLF1, BSLF1, and BXLF1 and their homologs encoded by other HHV members shows conservation of Cys residues that are involved in DUB
activity. The conserved residues are shown in white text with a black background, while similar residues in the alignment are shaded in gray. The
asterisk above the alignment indicates the Cys residues identified in the bioinformatics search. Mutations were introduced into the predicted
catalytic Cys residues, and the ability of the mutants to hydrolyze Ub-AMC was assayed as described in the legend to Fig. 3.
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the new putative DUBs was in both cases confirmed by the
capacity of the purified GST fusion proteins to cleave the
fluorogenic substrate Ub-AMC. Furthermore, the catalytic Cys
residues were identified in both proteins by mutation analysis,
confirming that these EBV ORFs are bona fide DUBs. It is
noteworthy that bacterially expressed full-length BSLF1 and
BXLF1 exhibited a poor enzymatic activity compared to both
the N-terminal portion of BPLF1 and the human DUB USP19
that was included as control. Comparison of the enzymatic
activity of purified proteins expressed in mammalian cells sug-
gests that this may be due to the requirement for posttransla-
tional modifications that are not achieved in bacteria. Indeed,
only the N terminus of UL36 was identified in the functional
screen performed in HSV-1-infected cells, suggesting that the
protein may be processed during infection.
The new viral DUBs identified in the present study are
expressed in the nucleus of EBV-infected cells during the early
phases of the productive virus cycle and, based on their anno-
tated functions, are involved in DNA replication and nucleo-
tide metabolism. It is noteworthy that the efficiency and fidelity
of DNA replication is regulated by posttranslational modifica-
tion of several components of the replication complex, includ-
ing for example, monoubiquitination, polyubiquitination, and
sumoylation of PCNA (36). The BSLF1 gene product shares
23% sequence identity with HSV UL52, the primase compo-
nent of the trimolecular helicase-primase complex was shown
to be essential to HSV replication (12, 13). In EBV the com-
plex is made up of BSLF1, BBLF4 (UL5 homolog), and
BBLF2/3 (UL8 homolog) (51), but its activity in viral replica-
tion has not been directly confirmed. Similar to UL52, BSLF1
contain several conserved amino acid domains, such as the
DxD motif (aa 481 to 498) and a putative zinc finger (Znf; aa
782 to 829) motif at the C-terminal end of protein that are also
found in prokaryotic and eukaryotic primases (7, 15, 24). Mu-
tational analysis of the Znf of HSV UL52 showed that this
region is required for the virus replication (7, 8, 10). The Znf
of BSLF1 partially overlaps with the predicted catalytic C-box.
BXLF1 gene encodes a protein of 607 aa that was annotated
as the EBV thymidine kinase (TK) gene due to its capacity to
complement TK-negative strains of E. coli (30) and partial
sequence homology with regions of HSV-1 TK (19). We found
that the regions that identify BXLF1 as a putative DUB and
the catalytic Cys residue are not conserved in other herpesvirus
homologues. Moreover, in contrast to other family members,
BXLF1 was shown to localize to the centrosomes, where it
encircles the tubulin-rich centrioles in a microtubule-indepen-
dent manner (20). It remains to be seen whether this atypical
localization may reflect a dual enzymatic activity that is not
present in the homologues.
In conclusion, we have shown that it is possible to use bioin-
formatics tools to identify distant homologues of DUBs en-
coded by viruses. Our strategy of choosing candidates based on
a global DUB score obtained by combining the results of mul-
tiple low stringency searches identified 16 high scoring ORFs
in a database of 106 putative or confirmed EBV ORFs. Enzy-
matic activity was confirmed for 3 of 11 ORFs tested, whereas
ORFs with low score and ORFs lacking putative C- or H-boxes
were uniformly negative. Thanks to its relatively good predic-
tive capacity, our approach could provide a valuable comple-
ment to the functional screening described by Kattenhorn et al.
(23), which, due to the requirement for validation by mass
spectroscopy, is strongly biased toward enzymes that are over-
expressed in the infected cells. Further studies will be required
to assess how the DUB activity of BPLF1, BSLF1, and BXL1
contributes to their role in virus replication and to the
remodeling of the cellular environment during productive
EBV infection.
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